Literature DB >> 19569976

Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey.

Martyn R Partridge1, Niklas Karlsson, Iain R Small.   

Abstract

OBJECTIVE: To determine diurnal variability of symptoms in chronic obstructive pulmonary disease (COPD) and to assess the impact of COPD upon patients' morning activities and routines. RESEARCH DESIGN AND METHODS: Quantitative internet interviews with 803 COPD patients from Europe and the USA, including 289 patients with severe COPD. Severe COPD was defined according to regular use of COPD medication, third level of breathlessness or above using the modified Medical Research Council (MRC) dyspnoea scale (MRC dyspnoea score > or =3) and one or more COPD exacerbations in the preceding 12 months.
RESULTS: Morning was the worst time of day for COPD symptoms, particularly in patients with severe COPD (reported by 46% of severe patients). In these patients, shortness of breath was the most frequently reported symptom, correlating strongly with problems experienced with morning activities. Morning activities most affected by COPD were walking up and down stairs, putting on shoes and socks, making the bed, dressing, showering or bathing and drying. The majority of patients were not taking their medication in time for it to exert its optimal effect.
CONCLUSIONS: Many patients consider the impact of COPD on morning activities to be substantial. Physicians should question patients about morning activities to assess disease impact and to advise regarding the optimal time to use therapy. This was an internet-based questionnaire survey and possible bias in patient selection and self-reported diagnosis of COPD and its severity should be taken into account.

Entities:  

Mesh:

Year:  2009        PMID: 19569976     DOI: 10.1185/03007990903103006

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  73 in total

Review 1.  Umeclidinium in chronic obstructive pulmonary disease: latest evidence and place in therapy.

Authors:  Kesavan Suresh Babu; Jaymin Bhagwanji Morjaria
Journal:  Ther Adv Chronic Dis       Date:  2017-03-24       Impact factor: 5.091

2.  Onset of action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease: a randomized, placebo-controlled, double-blind, crossover study.

Authors:  Mario Cazzola; Pierluigi Paggiaro; Paolo Palange; Leif Bjermer; Pilar Ausin; Lars-Goran Carlsson; Jan Ekelund; Jan Lotvall
Journal:  Clin Drug Investig       Date:  2012-03-01       Impact factor: 2.859

3.  A ferret model of COPD-related chronic bronchitis.

Authors:  S Vamsee Raju; Hyunki Kim; Stephen A Byzek; Li Ping Tang; John E Trombley; Patricia Jackson; Lawrence Rasmussen; J Michael Wells; Emily Falk Libby; Erik Dohm; Lindy Winter; Sharon L Samuel; Kurt R Zinn; J Edwin Blalock; Trenton R Schoeb; Mark T Dransfield; Steven M Rowe
Journal:  JCI Insight       Date:  2016-09-22

4.  Sleep complaints and sleep breathing disorders in upper and lower obstructive lung diseases.

Authors:  Matteo Ferrando; Diego Bagnasco; Valeria Roustan; Giorgio Walter Canonica; Fulvio Braido; Ilaria Baiardini
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

5.  Chronic obstructive pulmonary disease (COPD) patients' disease-related preferences : a study using conjoint analysis.

Authors:  Giovanni Pisa; Siegfried Freytag; Rainer Schandry
Journal:  Patient       Date:  2013       Impact factor: 3.883

6.  Perception of circadian variation of symptoms in Chinese patients with chronic obstructive pulmonary disease.

Authors:  Ming Lu; Xiaohong Wang; Baiqiang Cai; Kewu Huang; Jie Cao; Jinping Zheng; Yongchang Sun; Fuqiang Wen; Huili Zhu; Xin Zhou; Jianping Zhao; Yanfei Guo; Xia Ling; Wanzhen Yao
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

7.  Prediction and course of symptoms and lung function around an exacerbation in chronic obstructive pulmonary disease.

Authors:  Maarten van den Berge; Wim C J Hop; Thys van der Molen; Jan A van Noord; Jacques P H M Creemers; Ad J M Schreurs; Emiel F M Wouters; Dirkje S Postma
Journal:  Respir Res       Date:  2012-06-06

8.  Patient preference for a maintenance inhaler in chronic obstructive pulmonary disease: a comparison of Breezhaler and Respimat.

Authors:  Philip O'Hagan; Juergen Dederichs; Boomi Viswanad; Matthias Gasser; Susann Walda
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

9.  Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study.

Authors:  Edward Kerwin; Jacques Hébert; Nicola Gallagher; Carmen Martin; Tim Overend; Vijay K T Alagappan; Yimeng Lu; Donald Banerji
Journal:  Eur Respir J       Date:  2012-07-26       Impact factor: 16.671

Review 10.  Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD.

Authors:  Roland Buhl; Donald Banerji
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.